在接受皮肤穿左心室尾闭塞的患者中进行抗血栓治疗
1Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: https://twitter.com/RaberLorenz.
Interventional cardiology clinics
|September 8, 2024
概括
穿皮左心房尾关闭 (LAAC) 为心房动中预防中风提供了口服抗凝药的替代方案. 本综述审查了LAAC器件植入后的最佳抗血栓治疗,并解决了当前的不确定性和挑战.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血栓形成的管理
背景情况:
- 穿皮左心房尾关闭 (LAAC) 是预防心房患者缺血性中风的口服抗凝药的替代方案.
- LAAC设备含有金属,因此需要进行抗血栓治疗,以防止在设备表面形成血栓.
研究的目的:
- 审查LAAC装置植入后对抗血栓治疗的现有证据.
- 为了确定在LAAC后管理抗血栓策略的剩余挑战.
主要方法:
- 在LAAC之后对抗血栓治疗方案的现有文献进行系统审查.
- 对与设备相关的血栓形成和临床结果的数据分析.
主要成果:
- 目前的数据表明,需要针对LAAC后量身定制的抗血栓策略.
- 关于抗血栓治疗的最佳持续时间和类型的不确定性仍然存在.
结论:
- 在LAAC后最佳的抗血栓管理仍然是一个需要进一步研究的领域.
- 综合证据对于指导临床实践和LAAC治疗的未来研究至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


